Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy.


Journal Article

Twenty-seven patients with lymphoid neoplasia who underwent autologous bone marrow transplant (BMT) and who had received recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) were followed in order to examine the potential long-term consequences of rhGM-CSF. rhGM-CSF (15-240 micrograms/m2/day) was given daily either for 14 or 21 days after marrow infusion. All surviving patients who remained in remission had stable marrow graft function. The actuarial survival rate was 45% and the relapse incidence was 50% at a median of 774 days after autologous BMT. These findings suggest that treatment with rhGM-CSF does not have profound adverse long-term consequences.

Full Text

Duke Authors

Cited Authors

  • Nemunaitis, J; Singer, JW; Buckner, CD; Mori, T; Laponi, J; Hill, R; Storb, R; Sullivan, KM; Hansen, JA; Appelbaum, FR

Published Date

  • January 1, 1991

Published In

Volume / Issue

  • 7 / 1

Start / End Page

  • 49 - 52

PubMed ID

  • 2043878

Pubmed Central ID

  • 2043878

International Standard Serial Number (ISSN)

  • 0268-3369


  • eng

Conference Location

  • England